Literature DB >> 27410049

Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model.

Baihao Zhang1, Shunsuke Chikuma2, Shohei Hori3, Sidonia Fagarasan4, Tasuku Honjo5.   

Abstract

PD-1 (programmed-death 1), an immune-inhibitory receptor required for immune self-tolerance whose deficiency causes autoimmunity with variable severity and tissue specificity depending on other genetic factors, is expressed on activated T cells, including the transcription factor FoxP3(+) Treg cells known to play critical roles in maintaining immune tolerance. However, whether PD-1 expression by the Treg cells is required for their immune regulatory function, especially in autoimmune settings, is still unclear. We found that mice with partial FoxP3 insufficiency developed early-onset lympho-proliferation and lethal autoimmune pancreatitis only when PD-1 is absent. The autoimmune phenotype was rescued by the transfer of FoxP3-sufficient T cells, regardless of whether they were derived from WT or PD-1-deficient mice, indicating that Treg cells dominantly protect against development of spontaneous autoimmunity without intrinsic expression of PD-1. The absence of PD-1 combined with partial FoxP3 insufficiency, however, led to generation of ex-FoxP3 T cells with proinflammatory properties and expansion of effector/memory T cells that contributed to the autoimmune destruction of target tissues. Altogether, the results suggest that PD-1 and FoxP3 work collaboratively in maintaining immune tolerance mostly through nonoverlapping pathways. Thus, PD-1 is modulating the activation threshold and maintaining the balance between regulatory and effector T cells, whereas FoxP3 is sufficient for dominant regulation through maintaining the integrity of the Treg function. We suggest that genetic or environmental factors that even moderately affect the expression of both PD-1 and FoxP3 can cause life-threatening autoimmune diseases by disrupting the T-cell homeostasis.

Entities:  

Keywords:  PD-1; T lymphocytes; autoimmunity; immune tolerance; regulatory T cell

Mesh:

Substances:

Year:  2016        PMID: 27410049      PMCID: PMC4968716          DOI: 10.1073/pnas.1608873113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.

Authors:  T Okazaki; A Maeda; H Nishimura; T Kurosaki; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

2.  Faithful activation of an extra-bright red fluorescent protein in "knock-in" Cre-reporter mice ideally suited for lineage tracing studies.

Authors:  Hervé Luche; Odile Weber; Tata Nageswara Rao; Carmen Blum; Hans Jörg Fehling
Journal:  Eur J Immunol       Date:  2007-01       Impact factor: 5.532

3.  Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1.

Authors:  Masahiro Ono; Hiroko Yaguchi; Naganari Ohkura; Issay Kitabayashi; Yuko Nagamura; Takashi Nomura; Yoshiki Miyachi; Toshihiko Tsukada; Shimon Sakaguchi
Journal:  Nature       Date:  2007-03-21       Impact factor: 49.962

4.  Regulatory T cells: stability revisited.

Authors:  Samantha L Bailey-Bucktrout; Jeffrey A Bluestone
Journal:  Trends Immunol       Date:  2011-05-27       Impact factor: 16.687

5.  A self-reactive TCR drives the development of Foxp3+ regulatory T cells that prevent autoimmune disease.

Authors:  Justin R Killebrew; Nikole Perdue; Alan Kwan; Angela M Thornton; Ethan M Shevach; Daniel J Campbell
Journal:  J Immunol       Date:  2011-06-20       Impact factor: 5.422

Review 6.  Genetic polymorphism in FOXP3 gene: imbalance in regulatory T-cell role and development of human diseases.

Authors:  Julie Massayo Maeda Oda; Bruna Karina Banin Hirata; Roberta Losi Guembarovski; Maria Angelica Ehara Watanabe
Journal:  J Genet       Date:  2013-04       Impact factor: 1.166

7.  An N-terminal mutation of the Foxp3 transcription factor alleviates arthritis but exacerbates diabetes.

Authors:  Jaime Darce; Dipayan Rudra; Li Li; Junko Nishio; Daniela Cipolletta; Alexander Y Rudensky; Diane Mathis; Christophe Benoist
Journal:  Immunity       Date:  2012-05-10       Impact factor: 31.745

8.  Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells.

Authors:  Takahisa Miyao; Stefan Floess; Ruka Setoguchi; Hervé Luche; Hans Joerg Fehling; Herman Waldmann; Jochen Huehn; Shohei Hori
Journal:  Immunity       Date:  2012-02-09       Impact factor: 31.745

9.  Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.

Authors:  Brian T Fife; Indira Guleria; Melanie Gubbels Bupp; Todd N Eagar; Qizhi Tang; Helene Bour-Jordan; Hideo Yagita; Miyuki Azuma; Mohamed H Sayegh; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-11-20       Impact factor: 14.307

Review 10.  CD28 and CTLA-4 coreceptor expression and signal transduction.

Authors:  Christopher E Rudd; Alison Taylor; Helga Schneider
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

View more
  64 in total

1.  Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.

Authors:  Dennis O Adeegbe; Yan Liu; Patrick H Lizotte; Yusuke Kamihara; Amir R Aref; Christina Almonte; Ruben Dries; Yuyang Li; Shengwu Liu; Xiaoen Wang; Tiquella Warner-Hatten; Jessica Castrillon; Guo-Cheng Yuan; Neermala Poudel-Neupane; Haikuo Zhang; Jennifer L Guerriero; Shiwei Han; Mark M Awad; David A Barbie; Jerome Ritz; Simon S Jones; Peter S Hammerman; James Bradner; Steven N Quayle; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2017-04-13       Impact factor: 39.397

2.  Suppression of age-related salivary gland autoimmunity by glycosylation-dependent galectin-1-driven immune inhibitory circuits.

Authors:  Verónica C Martínez Allo; Vanesa Hauk; Nicolas Sarbia; Nicolás A Pinto; Diego O Croci; Tomás Dalotto-Moreno; Rosa M Morales; Sabrina G Gatto; Montana N Manselle Cocco; Juan C Stupirski; Ángel Deladoey; Esteban Maronna; Priscila Marcaida; Virginia Durigan; Anastasia Secco; Marta Mamani; Alicia Dos Santos; Antonio Catalán Pellet; Claudia Pérez Leiros; Gabriel A Rabinovich; Marta A Toscano
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-11       Impact factor: 11.205

Review 3.  Checkpoint Inhibitors: Applications for Autoimmunity.

Authors:  Anna S Tocheva; Adam Mor
Journal:  Curr Allergy Asthma Rep       Date:  2017-09-27       Impact factor: 4.806

Review 4.  Modulation of regulatory T cell function and stability by co-inhibitory receptors.

Authors:  Liliana E Lucca; Margarita Dominguez-Villar
Journal:  Nat Rev Immunol       Date:  2020-04-08       Impact factor: 53.106

5.  Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings.

Authors:  Ai Uchida; Maho Watanabe; Aya Nawata; Yosuke Ikari; Masaru Sasaki; Kana Shigemoto; Satoshi Hisano; Hitoshi Nakashima
Journal:  CEN Case Rep       Date:  2017-08-28

6.  LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes.

Authors:  Qianxia Zhang; Maria Chikina; Andrea L Szymczak-Workman; William Horne; Jay K Kolls; Kate M Vignali; Daniel Normolle; Maria Bettini; Creg J Workman; Dario A A Vignali
Journal:  Sci Immunol       Date:  2017-03-31

7.  Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells.

Authors:  Suchitra Prasad; Tobias Neef; Dan Xu; Joseph R Podojil; Daniel R Getts; Lonnie D Shea; Stephen D Miller
Journal:  J Autoimmun       Date:  2017-12-16       Impact factor: 7.094

8.  CD226 attenuates Treg suppressive capacity via CTLA-4 and TIGIT during EAE.

Authors:  Ning Wang; Shuang Liang; Jingyi Jin; Liang Fang; Qianli Ma; Xian Wang; Yun Song; Lihua Chen
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

9.  CD4+CD126low/- Foxp3+ Cell Population Represents a Superior Subset of Regulatory T Cells in Treating Autoimmune Diseases.

Authors:  Ye Chen; Zhenjian Xu; Rongzhen Liang; Julie Wang; Anping Xu; Ning Na; Bin Li; Ruoning Wang; Miller Joseph; Nancy Olsen; Willa Hsueh; Song Guo Zheng
Journal:  Mol Ther       Date:  2020-07-21       Impact factor: 11.454

10.  TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.

Authors:  David A Sallman; Amy F McLemore; Amy L Aldrich; Rami S Komrokji; Kathy L McGraw; Abhishek Dhawan; Susan Geyer; Hsin-An Hou; Erika A Eksioglu; Amy Sullivan; Sarah Warren; Kyle J MacBeth; Manja Meggendorfer; Torsten Haferlach; Steffen Boettcher; Benjamin L Ebert; Najla H Al Ali; Jeffrey E Lancet; John L Cleveland; Eric Padron; Alan F List
Journal:  Blood       Date:  2020-12-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.